Spero Therapeutics Signs License Agreement With Everest Medicines To Develop, Manufacture And Commercialize SPR206 In Asia, With Option For SPR741 Rights, Initiates SPR206 Phase 1 Clinical Trial ; Co. To Receive $2M Upfront And Up To $59.5M In Milestones
Benzinga Newsdesk